Why was a clozapine patient registry created?
Clozapine is known to be associated with a risk of developing agranulocytosis, a potentially life threatening condition. The risk of developing agranulocytosis is minimized by regular hematological monitoring. Access to the drug requires results of a blood test and the quantity dispensed is limited to a patients monitoring frequency as defined in the package insert.
